STOCK TITAN

Form 3 shows N2OFF director holds 490,751 common shares

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

N2OFF, Inc. (NITO) reported an initial statement of beneficial ownership on Form 3. The filing shows the reporting person is a Director and directly holds 490,751 shares of common stock.

The event date for this ownership report is 10/20/2025. No derivative securities were listed in the submission.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
SciSparc Ltd.

(Last) (First) (Middle)
20 RAUL WALLENBERG ST.

(Street)
TEL AVIV L3 6971916

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/20/2025
3. Issuer Name and Ticker or Trading Symbol
N2OFF, Inc. [ NITO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.0001 per share 490,751 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Oz Adler, Chief Executive Officer and Chief Financial Officer of SciSparc Ltd. 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did N2OFF, Inc. (NITO) disclose in this Form 3?

An initial statement of beneficial ownership indicating a Director directly holds 490,751 shares of common stock.

How many N2OFF (NITO) shares are beneficially owned according to the filing?

The filing reports 490,751 shares of common stock held directly.

What is the relationship of the reporting person to N2OFF (NITO)?

The reporting person is a Director.

What is the event date on the Form 3 for N2OFF (NITO)?

The date of event requiring the statement is 10/20/2025.

Were any derivative securities reported on this Form 3?

No derivative securities were listed in the provided table.

Was the Form 3 filed by one or multiple reporting persons?

It was filed by one reporting person.

Who signed the Form 3 and when?

It was signed by /s/ Oz Adler, Chief Executive Officer and Chief Financial Officer of SciSparc Ltd., on 10/24/2025.
Scisparc

NASDAQ:SPRC

SPRC Rankings

SPRC Latest News

SPRC Latest SEC Filings

SPRC Stock Data

5.27M
2.41M
0%
0.5%
9.3%
Biotechnology
Healthcare
Link
Israel
Tel Aviv